JPRN-UMIN000018178已完成未知
Prospective observational Study to explore the efficacy of Eribulin as 1st-line or 2nd-line chemotherapy in patients with HER2-negative hormone-resistant inoperable or recurrent metastatic breast cancer - E-SPEC
Kyoto Breast Cancer Research Network (KBCRN)0 个研究点目标入组 180 人开始时间: 2015年7月6日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 180
研究概览
简要总结
Among 201 patients enrolled, 180 were included in the final analysis. Eribulin was administered as first- and second-line chemotherapy to 46 (26.6%) and 70 (47.9%) patients, respectively. Median OS1 and OS2 were 2.25 (95% CI 1.07-2.68) and 1.75 (95% CI, 1.28-2.45) years for first- and second-line eribulin, respectively. Oral 5-FU followed by eribulin had a numerically longer OS1 (2.84 years) than the other sequences.
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1) Patients with symptomatic metastasis in the central nervous system. 2) Patients with a previous history of hypersensitivity to any component of drugs administered in the treatment. 3) Patients considered inappropriate for the study participation judged by the primary physician.
研究者
相似试验
招募中
不适用
Exploratory clinical study of eribulin followed by taxane for metastatic breast cancer patientsMetastatic breast cancerJPRN-UMIN000027527Yamaguchi University Graduate School of Medicine30
已完成
不适用
A Phase II Study of Eribulin Evaluating Efficacy and Safety as first or secondary line chemotherapy for advanced or metastatic breast cancer without HER2 overexpressingAdvanced or metastatic breast cancerJPRN-UMIN000009568General and Gastroenterological Surgery, Osaka Medical College35
未知
2 期
A study to evaluate the efficacy of Eribulin retreatment in HER2 negative Metastatic Breast Cancer patients - Phase II studyHER2-negative metastatic breast cancerJPRN-UMIN000027165Toho university30
已完成
不适用
A Study Of The Evaluation Of Patients Opulation With Erectile Dysfunction, Treated With SildenafilErectile DysfunctionNCT01108900Pfizer's Upjohn has merged with Mylan to form Viatris Inc.100
已完成
2 期
Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2Breast CancerNCT01593020M.D. Anderson Cancer Center54